Y
Yuxiu Liu
Researcher at Nankai University
Publications - 268
Citations - 5038
Yuxiu Liu is an academic researcher from Nankai University. The author has contributed to research in topics: Chemistry & Catalysis. The author has an hindex of 31, co-authored 227 publications receiving 3378 citations. Previous affiliations of Yuxiu Liu include Syngenta & West Virginia University.
Papers
More filters
Journal ArticleDOI
Highly Efficient Synthesis and Acaricidal and Insecticidal Activities of Novel Oxazolines with N-Heterocyclic Substituents.
TL;DR: In this article, a series of novel 2,4-diphenyl-1,3-oxazolines bearing various N-heterocyclic substituents via a 4-(4-(chloromethyl)phenyl)-2-(2,6-difluorophenyl)-4,5-dihydrooxazole intermediate generated by a modified Ritter reaction were reported.
Journal ArticleDOI
Additive effects on the improvement of insecticidal activity: Design, synthesis, and insecticidal activity of novel pymetrozine derivatives.
TL;DR: Compound IIIs, containing an allyl at the para position of phenoxy group, exhibited excellent insecticidal activity against mosquito larvae, lepidoptera pests cotton bollworm, corn borer and oriental armyworm.
Journal ArticleDOI
Visible-light-mediated three-component Minisci reaction for heteroarylethyl alcohols synthesis
TL;DR: In this article, a mild, modular, practical Minisci reaction for catalytic synthesis of heteroarylethyl alcohols via sequential addition of H2O and N-heteroarenes across olefinic double bonds is presented.
Journal ArticleDOI
Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of glycoconjugates of phenanthroindolizidines alkaloids.
TL;DR: Glycoconjugates of phenanthroindolizidine alkaloids targeting tobacco mosaic virus (TMV) RNA displayed significant higher activity than commercial ningnanmycin, and thus could be considered for novel therapy against plant virus infection.
Journal ArticleDOI
Hydroxyl May Not Be Indispensable for Raltegravir: Design, Synthesis and SAR Studies of Raltegravir Derivatives as HIV-1 Inhibitors.
TL;DR: A variety of raltegravir derivatives such as (I) and (II) is synthesized and systematically evaluated for their anti-HIV activity.